U.S. halts distribution of Eli Lilly’s coronavirus antibody treatment bamlanivimab as a monotherapy

The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab (LY-CoV555) as a monotherapy just four months after it received FDA emergency use authorization, citing a sustained increase in variants of SARS-CoV-2 that are resistant to the monotherapy....More...

“Escape mutations” could help SARS-CoV-2 evade immune attack

Researchers in the United States have identified mutations within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that can reduce antibody binding to the virus, potentially mediating its escape from immune attack.… ...More...